XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 132; DB 5; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.4e-13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NLWAAQRYGRELRRMSDEFVDSFKK 25
||||||||||||||||||||||||||
Db 1 NLWAAQRYGRELRRMSDEFVDSFKK 25

RESULT 2
ABP56161
ID ABP56161 standard; peptide; 25 AA.
XX
AC ABP56161;
XX
DT 28-MAR-2003 (first entry)
XX
DE PTPC-interacting TOX peptide #27.
XX
KW Mitochondrial membrane permeabilisation; mitochondrion; PTPC;
KW permeability transition pore complex; virucide; neuroprotective;
KW vasotropic; cytostatic; infection; cell death regulation; apoptosis;
KW mitochondrial permeability transition pore complex modulator; cancer;
KW apoptogenic; ischaemia; neurodegenerative disease; fulminant hepatitis.
XX
OS Synthetic.
XX
PN WO200261105-A2.
XX
PD 08-AUG-2002.
XX
PF 01-FEB-2002; 2002WO-EP001633.
XX
PR 02-FEB-2001; 2001US-0265594P.
XX
PA (INSP ) INST PASTEUR.
PA (CNRS ) CENT NAT RECH SCI.
XX
PI Edelman L, Jacotot E, Briand J;
XX
DR WPI; 2002-619260/66.
XX
PT New chimeric bifunctional molecules that target specific cells and
PT regulate the apoptosis function of the permeability transition pore
PT complex of the mitochondria, useful for treating or preventing e.g.
PT cancer or ischemia.
XX
PS Claim 9; Page 11; 76pp; English.
XX
CC The present invention describes a chimeric bifunctional molecule (I)
CC comprising at least a first functional molecule covalently linked to a
CC second functional molecule, which is able to modulate the activity of the
CC permeability transition pore complex (PTPC) of the mitochondria. (I) has
CC the function of specifically targeting and entering a tissue cell
CC population. The second functional molecule has the function of
CC specifically targeting, and inducing or preventing the death of the cells
CC by apoptosis by regulating the opening or the closing of the PTPC of the
CC mitochondria or its fragment. (I) has virucide, neuroprotective,
CC vasotropic and cytostatic activities, and can be used as a mitochondrial
CC permeability transition pore complex (PTPC) modulator. (I) is useful for
CC treating or preventing a pathological infection or disease. (I) is also
CC useful for regulating cell death regulatory molecules, specifically the
CC apoptogenic function of the PTPC, for treating e.g. cancer, ischaemia,
CC neurodegenerative diseases, fulminant hepatitis or viral infections. The
CC present sequence represents a PTPC-interacting TOX peptide which is given
CC in the exemplification of the present invention
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 132; DB 5; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.4e-13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NLWAAQRYGRELRRMSDEFVDSFKK 25
||||||||||||||||||||||||||
Db 1 NLWAAQRYGRELRRMSDEFVDSFKK 25

RESULT 3
AAU78610
ID AAU78610 standard; peptide; 25 AA.
XX
AC AAU78610;
XX
DT 18-JUN-2002 (first entry)
XX
DE Human Bad peptide #10 which binds to a member of the Bcl-2 family.
XX
KW Human; Bad; Bcl-2; apoptosis; cancer; inducer; degenerative disease;
KW ischemic injury; suppressor; BH3 domain.
XX
OS Homo sapiens.
XX
PN WO200220568-A2.
XX
PD 14-MAR-2002.
XX
PF 04-SEP-2001; 2001WO-US027410.
XX
PR 06-SEP-2000; 2000US-00656399.
XX
PA (ABBO ) ABBOTT LAB.
XX
PI Fesik SW, Meadows RP, Joseph MK, Olejniczak ET, Petros AM;
PI Nettesheim DG, Swift KM, Matayoshi E, Zhang H;
XX
DR WPI; 2002-292254/33.
XX
PT New derivatives of Bad peptide, useful for identifying compounds that
PT bind to Bcl-2 proteins, potential agents for treating cancer and
PT degenerative disease.
XX
PS Claim 18; Page 18; 31pp; English.
XX
CC The present invention relates to new peptides that are derived from a
CC wild-type human Bad peptide and are able to bind to a member of the Bcl-2
CC protein family. The peptides are useful, when labelled, in
CC competitive/displacement assays for identifying substances that bind to
CC members of the Bcl-2 family and may induce or suppress apoptosis so are
CC potentially useful for treating cancer (inducers) or degenerative
CC diseases or ischemic injury (suppressors). The peptides of the invention
CC have high helix propensity, maintain the contacts of the wild-type Bad
CC peptide and, compared with the Bad peptide, may have better physical
CC properties, particularly solubility. The present sequence represents one
CC of a collection of Bad peptides (AAU78601-AAU78631) that were derived
CC from the BH3 domain of the human wild-type Bad peptide
XX
SQ Sequence 25 AA;

Query Match 100.0%; Score 132; DB 5; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.4e-13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NLWAAQRYGRELRRMSDEFVDSFKK 25
||||||||||||||||||||||||||
Db 1 NLWAAQRYGRELRRMSDEFVDSFKK 25

RESULT 4
ADK90776
ID ADK90776 standard; peptide; 25 AA.
XX
AC ADK90776;

Seq ID NO: 10

Exhibit A

Exhibit B

```
RESULT 2
US-08-717-123-2
; Sequence 2, Application US/08717123
; Patent No. 5965703
;  GENERAL INFORMATION:
;    APPLICANT:  Horne, William A.
;    APPLICANT:  Oltersdorf, Tilman
;    TITLE OF INVENTION:  Human BAD Polypeptides, Encoding Nucleic
;    TITLE OF INVENTION:  Acids and Methods of Use
;    NUMBER OF SEQUENCES:  15
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell and Flores
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  United States
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/717,123
;      FILING DATE:  20-SEP-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-ID 1929
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-8949
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  168 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
US-08-717-123-2

  Query Match             100.0%;  Score 132;  DB 1;  Length 168;
  Best Local Similarity   100.0%;  Pred. No. 7.9e-13;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 NLWAAQRYGRELRRMSDEFVDSFKK 25
              |||||||||||||||||||||||||
Db        103 NLWAAQRYGRELRRMSDEFVDSFKK 127


RESULT 3
US-08-985-335-1
; Sequence 1, Application US/08985335
; Patent No. 6080847
;  GENERAL INFORMATION:
;    APPLICANT:  Hillman, Jennifer L.
;    APPLICANT:  Yue, Henry
;    APPLICANT:  Lal, Preeti
;    APPLICANT:  Shah, Purvi
;    APPLICANT:  Corley, Neil C.
;    TITLE OF INVENTION:  PROTEINS ASSOCIATED WITH CELL
;    TITLE OF INVENTION:  PROLIFERATION
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Incyte Pharmaceuticals, Inc.
;      STREET:  3174 Porter Dr.
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,335
;      FILING DATE:  Filed Herewith
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Billings, Lucy J.
;      REGISTRATION NUMBER:  36,749
;      REFERENCE/DOCKET NUMBER:  PF-0421 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-855-0555
;      TELEFAX:  650-845-4166
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  168 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    IMMEDIATE SOURCE:
;      LIBRARY:  SYNORAB01
;      CLONE:  358673
US-08-985-335-1

  Query Match             100.0%;  Score 132;  DB 2;  Length 168;
  Best Local Similarity   100.0%;  Pred. No. 7.9e-13;
  Matches   25;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 NLWAAQRYGRELRRMSDEFVDSFKK 25
              |||||||||||||||||||||||||
Db        103 NLWAAQRYGRELRRMSDEFVDSFKK 127


RESULT 4
US-08-985-335-7
; Sequence 7, Application US/08985335
; Patent No. 6080847
;  GENERAL INFORMATION:
;    APPLICANT:  Hillman, Jennifer L.
;    APPLICANT:  Yue, Henry
;    APPLICANT:  Lal, Preeti
;    APPLICANT:  Shah, Purvi
;    APPLICANT:  Corley, Neil C.
;    TITLE OF INVENTION:  PROTEINS ASSOCIATED WITH CELL
;    TITLE OF INVENTION:  PROLIFERATION
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Incyte Pharmaceuticals, Inc.
;      STREET:  3174 Porter Dr.
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,335
;      FILING DATE:  Filed Herewith
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Billings, Lucy J.
;      REGISTRATION NUMBER:  36,749
;      REFERENCE/DOCKET NUMBER:  PF-0421 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-855-0555
;      TELEFAX:  650-845-4166
```